Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.00005 par value
-
Shares outstanding
-
7.18M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
236K
-
Shares change
-
-630K
-
Total reported value, excl. options
-
$264K
-
Value change
-
-$805K
-
Number of buys
-
11
-
Number of sells
-
-8
-
Price
-
$1.12
Significant Holders of BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) as of Q2 2025
38 filings reported holding BCLI - BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value as of Q2 2025.
BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 236K shares
of 7.18M outstanding shares and own 3.28% of the company stock.
Largest 10 shareholders include GEODE CAPITAL MANAGEMENT, LLC (54.6K shares), VANGUARD GROUP INC (27.7K shares), Gunderson Capital Management Inc. (26K shares), BlackRock, Inc. (25.2K shares), LIBERTY WEALTH MANAGEMENT LLC (22.7K shares), Weaver Consulting Group (15.6K shares), UBS Group AG (12.4K shares), Traynor Capital Management, Inc. (11K shares), LPL Financial LLC (10.7K shares), and Almanack Investment Partners, LLC. (10K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.